Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND: Venlafaxine in Japanese Major Depressive Disorder With or Without Anxious Distress
jRCT1031230620Active, not recruiting
- Sponsor
- Viatris
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of venlafaxine in major depressive disorder (MDD), sponsored by Viatris. Primary endpoint: Change in MADRS total score. Started May 2024; status: active, not recruiting.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT1031230620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230620.